Asset Details
Do you wish to reserve the book?
Tumor‐derived exosomal proteins as diagnostic biomarkers in non‐small cell lung cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Tumor‐derived exosomal proteins as diagnostic biomarkers in non‐small cell lung cancer
Do you wish to request the book?
Tumor‐derived exosomal proteins as diagnostic biomarkers in non‐small cell lung cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Tumor‐derived exosomal proteins as diagnostic biomarkers in non‐small cell lung cancer
2019
Overview
Accumulating evidence supports a role for exosomal protein in diagnosis. The purpose of this study was to identify the tumor‐derived exosomal biomarkers in the serum that improve the diagnostic value in Chinese non‐small cell lung cancer (NSCLC) patients. Serum exosomes were isolated from healthy donors (n = 46) and NSCLC patients (n = 125) by ultracentrifugation and were characterized using transmission electron microscopy, qNano, and immunoblotting. Proteomic profiles (by mass spectrometry) revealed multiple differentially expressed proteins in the healthy and NSCLC groups. The exosomal expression levels of alpha‐2‐HS‐glycoprotein (AHSG) and extracellular matrix protein 1 (ECM1) increased significantly in the NSCLC patients compared to the healthy group. Alpha‐2‐HS‐glycoprotein showed diagnostic values with a maximum area under the receiver operating characteristic curve (AUC) as 0.736 for NSCLC vs healthy individuals (P < .0001) and 0.682 for early stage NSCLC vs healthy individuals (P < .01). Extracellular matrix protein 1 showed the diagnostic capacity with AUC values of 0.683 (P < .001) and 0.656 (P < .05) in cancer and early stage NSCLC compared to healthy individuals. When AHSG was combined with ECM1, the AUCs were 0.795 and 0.739 in NSCLC and early stage patients, respectively. Taken together, the combination of AHSG, ECM1, and carcinoembryonic antigen improved the diagnostic potential of NSCLC. The diagnosis values were AUC of 0.938 for NSCLC and 0.911 for early stage NSCLC vs healthy individuals. Our results suggest that novel proteomic signatures found in serum exosomes of NSCLC patients show potential usefulness as diagnostic tools. The combination of alpha‐2‐HS‐glycoprotein, extracellular matrix protein 1, and carcinoembryonic antigen improved the diagnostic potential of non‐small cell lung carcinoma (NSCLC). The diagnostic values were areas under the receiver operating characteristic curves of 0.938 for NSCLC and 0.911 for early stage NSCLC vs healthy individuals.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
Subject
/ Aged
/ alpha-2-HS-Glycoprotein - metabolism
/ Biomarkers, Tumor - metabolism
/ Biopsy
/ Carcinoembryonic Antigen - blood
/ Carcinoembryonic Antigen - metabolism
/ Carcinoma, Non-Small-Cell Lung - diagnosis
/ Carcinoma, Non-Small-Cell Lung - metabolism
/ Disease
/ Exosomes
/ extracellular matrix protein 1
/ Extracellular Matrix Proteins - blood
/ Extracellular Matrix Proteins - metabolism
/ Female
/ Humans
/ Male
/ Microscopy, Electron, Transmission
/ Neoplasm Proteins - metabolism
/ Non-small cell lung carcinoma
/ Original
/ Proteins
/ Software
/ Transmission electron microscopy
/ Tumors
